Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Abbott Clocks Q1 COVID-19 Test Sales Of $3.3B, Reaffirms FY22 EPS Outlook

  • Abbott Laboratories (NYSE:ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50.
  • Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion.
  • Worldwide sales, excluding COVID-19 testing-related sales, increased 3.9% on a reported basis and 7.7% on an organic basis.
  • Related: Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings.
  • Global COVID-19 testing-related sales were $3.3 billion, led by sales of rapid testing products.
  • Medical Devices sales increased 7.4% to $3.56 billion on a reported basis and 11.5% organically, driven by double-digit organic growth in Electrophysiology, Heart Failure, Structural Heart and Diabetes Care.
  • Outlook: Abbott's FY22 adjusted EPS outlook of at least $4.70 remains unchanged (consensus $4.83).
  • 2022 guidance includes projected COVID-19 testing-related sales of approximately $4.5 billion, which Abbott expects to primarily occur in 1H of 2022 and will update quarterly.
  • Price Action: ABT shares are down 2.07% at $117.50 during the premarket session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.